



# ASX Announcement

1 September 2021

## AnteoTech positions Board for growth and establishes Advisory Boards

### Highlights

- ❖ Appointment of Ms Glenda McLoughlin and Dr Katherine Woodthorpe AO as non-executive directors
- ❖ AnteoTech establishes Advisory Boards to support the Life Sciences and Energy businesses
- ❖ Energy Advisory Board to be founded by Mr. Oliver Gross and Dr Kevin Eberman
- ❖ Clinical Advisory Board to be founded by Prof. Paul Young and Prof. Dominic Dwyer

AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") is pleased to announce the appointments of two new independent Non-Executive Directors to the Company, Ms Glenda McLoughlin and Dr Katherine Woodthorpe effective 1 September 2021. The appointments fill casual vacancies on the board and bring additional skills and experience to the Board.

The appointments follow a thorough recruitment process fulfilling the Board's commitment to ensuring the diversity of skills and expertise of the Board to meet the current and longer-term strategic objectives of the Company.

In addition to the appointment of the two Non-Executive Directors, the Board is pleased to announce the formation of two Advisory Boards with the appointment of Prof. Paul Young and Prof. Dominic Dwyer to the Clinical Advisory Board and Mr. Oliver Gross and Dr Kevin Eberman to the Energy Advisory Board.

AnteoTech Chair Dr Jack Hamilton said "AnteoTech has undergone a significant transformation over the past 12 months as we continue to execute our strategy and transition to be a global supplier of solutions to the rapid diagnostic and battery industries. We are delighted that both Katherine and Glenda have agreed to bring their considerable talents and experience to AnteoTech to assist in continuing this trajectory. We are confident that their combined experience, and industry knowledge will add significant value to the Board."

### Ms Glenda McLoughlin

Ms. Glenda McLaughlin is an experienced Non-Executive Director with over 25 years' experience as an Investment Banker and Senior Executive working in Australia, Asia, the UK and the US. She has held senior executive roles at leading financial institutions Morgan Stanley, Credit Suisse and Barclays Capital where she led the Energy and Infrastructure Group in Australia. In addition to her work in the energy sector, Glenda has experience in the medical diagnostics, telecommunications, information technology, media, transport and financial services sectors. Glenda co-founded listed Australian gas

company Metgasco Ltd, where she was Executive Director and Chief Financial Officer for eight years. Glenda holds a Bachelor of Economics and Master of Business Administration and is a Fellow of the Australian Institute of Company Directors.

Ms. McLoughlin currently holds the positions of Non-Executive Director with Senex Energy Ltd where she chairs the Audit and Risk Committee and is Chair of SCEGGS Redlands.

Ms McLoughlin will become Chair of AnteoTech's Audit and Risk Committee.

### **Dr Katherine Woodthorpe AO**

Dr Katherine Woodthorpe AO is an experienced Chair and Non-Executive Director serving for 20 years on the boards of a variety of organisations including listed entities, government boards and for-purpose organisations. She has a strong track record in a broad range of innovation-dependent industries including healthcare, renewable energy and environmental and climate science. She has been cited in various media as one of Australia's most influential people in innovation. Katherine has deep knowledge of the private equity and venture capital industries in the financial sector as well as working closely with superannuation funds on their alternative investments in the private equity space. For seven years she was the Chief Executive of AVCAL, the Australian Private Equity and Venture Capital Association. Prior to AVCAL, she held a broad range of management and board positions, in Australia and overseas. Katherine commenced her career initially as a chemist then moved to sales of specialised laboratory equipment into the medical and oil, gas and petrochemical sectors covering the geographies of Europe, Asia and the Middle East before locating permanently to Australia in 1988. Katherine holds a Bachelor of Science (Manchester Uni.) and Ph.D. (Chemistry, Leicester Uni, UK).

Dr. Woodthorpe, amongst several positions, is a Non-Executive Director of the Olivia Newton John Cancer Research Institute, Bioplatforms Australia Ltd and Vast Solar Pty Ltd.

### **Advisory Boards**

To support the rapid growth and commercialisation of its products the Board has approved the formation of a Clinical Advisory Board and an Energy Advisory Board. These Advisory Boards will comprise initially of two external members and each will be chaired by a member of the AnteoTech Board. Their roles are to advise and support the Company's current and future development.

The Advisory Boards will support the AnteoTech Board and senior management in their respective capacities. The Clinical Advisory Board will focus on supporting the development of a pipeline of Point of Care tests using AnteoTech's AnteoBind activated Europium particles combined with its EuGeni reader platform. The Energy Advisory Board will focus on the development, application and commercialisation of AnteoTech's IP in enhancing the energy density of lithium-ion anodes through increased use of silicon.

The Advisory Boards will report to the AnteoTech Board acting in an advisory capacity and have no decision authority, or implementation responsibility. The AnteoTech CEO will be joined by the Head of Life Sciences and Head of Energy as ex-officio members of their respective Advisory Boards.

AnteoTech Chairman Dr. Jack Hamilton welcomed the new appointees to the Advisory Boards "AnteoTech is fortunate to be joined by these four individuals and have access to the breadth of experience and insight they bring. Oliver, Kevin, Paul and Dominic's appointments bring an extensive

network in business, technology, and innovation experience in their relevant fields to the company. They are well placed to guide and support our executive team, and they will bring valuable strategic insights to the AnteoTech Board. The Board looks forward to their contribution to the future of the company."

## **Clinical Advisory Board**

### **Prof Paul Young**

Paul Young is Professor of Virology and Head of School (School of Chemistry & Molecular Biosciences) at the University of Queensland, Brisbane, Australia. He completed his basic science degree in Australia before moving to the UK where he was awarded his PhD in 1986 from the London School of Hygiene & Tropical Medicine. He began his dengue research program at the LSHTM, initially in the area of vaccine development supported by the World Health Organisation (WHO). He returned to Australia in 1989 and joined the University of Queensland in 1991. His current interests are in the molecular virology, diagnosis, vaccine and therapeutic control of dengue and West Nile viruses as well as respiratory syncytial virus and emerging virus infections. He is also investigating the current invasion of the koala genome by a novel retrovirus and its impact on disease in this iconic species.

Paul is a past President of the Australian Society for Microbiology, the Australasian Virology Society and the South East Asian Society for Medical Virology.

### **Prof Dominic Dwyer**

Professor Dominic Dwyer trained in microbiology (virology and infectious diseases) at Westmead Hospital's Institute of Clinical Pathology and Medical Research (ICPMR) in 1986 and became a medical microbiologist in 1997. In 2009, Professor Dwyer was appointed Director and Senior Medical Virologist for ICPMR's Centre for Infectious Diseases and Microbiology Laboratory Services, part of NSW Health Pathology.

Dominic has extensive experience in pandemic responses, even prior to COVID-19. His work in molecular testing for HIV spans three decades. In 2020 he was selected by the WHO, to be part of a 15 member international team to work with local health officials in Wuhan to explore the origins of the coronavirus.

He is currently a Clinical Professor at the University of Sydney's Western Clinical School and recently spent 12 months as a visiting academic in the Service des Maladies Infectieuses et Tropicales at the Hospital Saint-Louis, a public teaching hospital in Paris.

## **Energy Advisory Board**

### **Mr Oliver Gross**

Oliver Gross holds both a BS and a Master's Degree in Materials Science from the University of Toronto. Oliver has 20 years' experience in the advanced energy storage industry. He currently holds the position of Walter P. Chrysler Technical Fellow, for Energy Storage Systems, at Stellantis (formally Fiat Chrysler Automobiles), where he is responsible for the Battery systems technology roadmap and architecture. He is a member of the United States Advanced Battery Consortium Technical Advisory Committee and chairs the committees on 12V Stop-Start and 48V Mild Hybrid batteries. He is also Chairman for the Society for Automotive Engineers' Work Group on Capacitive Energy Storage Systems.

Prior to Chrysler Oliver was at Cobasys, where he was responsible for all Nickel Metal-Hydride cell and module development and the development of their lithium-ion battery portfolio. Before Cobasys, Oliver was at Valence Technology, where he was responsible for lithium-ion cell design and development, which included extended-term deployments to Northern Ireland, South Korea, and China. Before Valence, Oliver was at Ultralife, developing lithium primary and secondary cells for extreme environment applications. He currently holds over 10 patents, and more than 20 publications.

#### **Dr Kevin Eberman**

Kevin Eberman received his Ph.D. in Materials Science at the Massachusetts Institute of Technology in 1998. Following a post-doctoral appointment at the Max Planck Institute for Solid-State Research, where he had a paper published in Nature, he commenced at 3M in the Lithium-ion battery (LIB) group developing anode and cathode materials for LIBs. Dr Eberman was the technical lead in launching a new class of the cathode materials called “NMC”. From 2006 to 2010 he worked at Medtronic as a Principal Scientist in the battery research group, contributing to Lithium-ion and primary battery research, development, and production.

In 2010 he re-joined 3M in a management role for the LIB research group. In addition to developing electrolyte, binder, current-collector, and high-voltage cathode materials, the 3M team developed the leading Si-alloy materials. Dr Eberman currently provides technical leadership for the development of improved batteries for 3M's line of professional safety equipment and advises on all things battery at 3M. He has 22 publications and 11 patents or patent applications.

This announcement has been authorised for release by the Board.

#### **For more information, please contact:**

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

#### **ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)**

AnteoTech is a surface chemistry company with Intellectual Property (“IP”) in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company’s purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit [www.anteotech.com](http://www.anteotech.com)

